This page is the continuation of reference in support of Section 4b.
REFERENCES
American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition, Edge, S.B., Byrd, D.R., Compton, C.C., et al (Eds), Springer, New York 2010.
Bernstein, L. The epidemiology of breast carcinoma in situ. In: Silverstein ML, editor. Ductal Carcinoma In Situ of the Breast. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2002.
Bijker, N., Meijnen, P., Peterse, J.L., et al. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III Trial 10853—A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381-3387. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16801628
Bradley, S.J., Weaver, D.W., Bowman, D.L. (1990). Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome.
Chuba, P.J., Hamre, M.R., Yap, J., Severson, R.K., Lucas, D., Shamsa, F., Aref, A. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23(24):5534. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/16110014
Collins, L.C., Baer, H.J., Tamimi, R.M., Connolly, J.L., Colditz, G.A., Schnitt, S.J. (2007). Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses’ Health Study. Cancer 109(2), 180. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/17154175
Dupont, W.D., Page, D.L. (1985). Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3), 146-151. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/3965932
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Gray, R. (et al). (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Lancet. 2005 May 14-20;365(9472):1687-717 (Retrieved November 6th 2014): http://www.ncbi.nlm.nih.gov/pubmed/15894097
Marshall, L.M>, Hunter, D.J., Connolly, J.L., Schnitt, S.J., Byrne, C., London, S.J., Colditz, G.A. (1997). Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. May;6(5):297-301. (Retrieved January 12th 2014) http://www.ncbi.nlm.nih.gov/pubmed/9149887
Page, D.L., Schuyler, P.A., Dupont, W.D., Jensen, R.A., Plummer,W.D. Jr, Simpson, J.F. (2003). Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361(9352), 125. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/12531579
Schairer, C., Mink, P.J., Carroll, L., et al. (2004). Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96, 1311-1321. (Retrieved November 6th 2014): https://academic.oup.com/jnci/article/96/17/1311/2520929
Schonberg, M.A., Marcantonio, E.R., Ngo, L., Li, D., Silliman, R.A., McCarthy, E.P. (2011). Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 29(12), 1570. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/21402602
Schwartz, T., Cyr, A., Margenthaler, J. (2014). Screening breast magnetic resonance imaging in women with atypia or lobular carcinoma in situ. J Surg Res S0022-4804. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/25277350
Staley, H., McCallum, I., Bruce, J. (2012). Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 10, CD007847. (Retrieved November 6th 2014): https://www.ncbi.nlm.nih.gov/pubmed/23076938
